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Clinical issues in cannabis use
Abstract

2018 The British Pharmacological Society Cannabis is the most commonly used illicit substance worldwide
and the prevalence of users continues to increase. Over the last 2 decades, the world has seen significant
changes regarding cannabis for recreational use as well as application in its use as a therapeutic medicine. This
is likely to have influenced the decreasing perception of risks associated with the use of cannabis. Cannabis,
however, is not benign and, depending on the pattern of its use, can incur a range of harmful effects, which
have implications when prescribing medicinal cannabinoids for individuals. Based on research evidence from
recreational use of cannabis as well as the emerging data from trials of medicinal cannabis, we propose some
clinical domains that will need specific considerations when prescribing medicinal cannabis.
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Cannabis is the most commonly used illicit substance worldwide and the prevalence of users continues to increase. Over the last 2
decades, the world has seen signiﬁcant changes regarding cannabis for recreational use as well as application in its use as a
therapeutic medicine. This is likely to have inﬂuenced the decreasing perception of risks associated with the use of cannabis.
Cannabis, however, is not benign and, depending on the pattern of its use, can incur a range of harmful effects, which have
implications when prescribing medicinal cannabinoids for individuals. Based on research evidence from recreational use of
cannabis as well as the emerging data from trials of medicinal cannabis, we propose some clinical domains that will need speciﬁc
considerations when prescribing medicinal cannabis.

Introduction
Cannabis is the most commonly used illicit substance worldwide [1] and the prevalence of users continues to increase.
Over the last 2 decades, there have been signiﬁcant changes
around the world regarding cannabis, including decriminalization, and in some states or countries, legalization for recreational use as well as access to cannabinoids for use as a
therapeutic medicine. Some, albeit not all, countries where
changes in relation to cannabis have occurred include
Canada, Australia, Israel, Uruguay, the USA, and some European and Scandinavian countries. This is likely to have inﬂuenced the decreasing perception of risks associated with the
use of cannabis. Cannabis, however, is not benign and depending on the pattern of its use, can incur a range of harmful
effects, which have implications when prescribing medicinal
cannabinoids for individuals.
Therapeutic indications for cannabis are assumed to
target the endocannabinoid system, which has receptors
(CB1 and CB2) involved in cognition, memory, analgesia,
psychomotricity, appetite and immune function. There are,
however, few data speciﬁcally on the efﬁcacy of medicinal
cannabinoids for the various indications suggested to date.
© 2018 The British Pharmacological Society

There are even fewer data for a variety of speciﬁc populations
such as pregnancy, young people, elderly individuals with
complex comorbidities and those with mental health issues.
Substantial reliance on research evidence from recreational
use of cannabis is therefore required until robust data specifically for medicinal cannabinoids become available.
A broad range of therapeutic effects of cannabinoids has
been suggested [2] and is currently the focus of much research. Delta-9-tetrahydrocannabinol (THC) has been proposed to be of beneﬁt for chronic pain, nausea and vomiting
induced by chemotherapy, and in the reduction of spasms in
multiple sclerosis [2]. Cannabidiol (CBD) has antipsychotic,
anxiolytic and anticonvulsant properties and may reduce
Parkinsonian symptoms [2]. As the evidence base for clinical
indications for medicinal cannabinoids becomes clearer,
certain populations will require further special consideration:

Young people prescribed medicinal
cannabinoids
Cannabis is the most common illicit substance used by youth
in the western world. Evidence from this nonmedical use
DOI:10.1111/bcp.13703
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indicates that frequent use of cannabis during adolescence is
associated with a range of adverse psychosocial outcomes in
young adulthood, including other substance use and poorer
educational attainment and mental health [3]. Alterations
to the structure and function of the brain associated with exposure to cannabis, particularly of high THC content, is
concerning for the developing brain [4–6]. Long-term medicinal cannabinoids may be contraindicated in this population
unless the condition is life limiting or severely debilitating.
There is some evidence of beneﬁt in children and adolescents
for chemotherapy-induced nausea and vomiting and potentially for epilepsy, but adverse effects are under-investigated
at present [7].

Mental health

Elderly individuals

Addiction

Elderly individuals may also be sensitive to the cognitive
effects of cannabis. There is growing concern that cannabis
use may be associated with dementia. Similarly, the cardiometabolic proﬁle of medicinal cannabinoids needs clariﬁcation, as this is especially important in the context of
complex comorbidities in elderly individuals who often have
a combination of cardiovascular disease, diabetes, liver or renal impairment [1, 2].

Estimates suggest that over 180 million people use cannabis
for nonmedical, or recreational, purposes globally and that
approximately 13 million people are dependent on cannabis [11]. The number of cannabis users seeking treatment
for cannabis use disorder has increased over the past 2
decades in many countries such as Australia, Europe and
the USA. European ﬁgures show that the number of users
who started treatment for the ﬁrst time due to cannabis-related problems has increased by >75% in 10 years [12]. This
increase in the demand for treatment may be linked to a
number of factors. The increased prevalence of cannabis
use, including heavy use, in the general population, increased concentration of THC in street cannabis, and higher
prevalence rates of self-medication with cannabis. Given
this, and as occurs with all drugs with addiction liability,
the potential for misuse (deﬁned as use that is not as prescribed or use in individuals for whom there are contraindications to use), or diversion (deﬁned as use by individuals
for whom the prescription was not intended) of medically
prescribed cannabinoids (especially THC) needs to be anticipated and managed to reduce public health harm [13].
Future prevalence of dependence or addiction in those prescribed medicinal cannabinoids is difﬁcult to predict. The
current prescription opioid crisis in the western world, however, is a salient reminder that when prescribed widely, in
high-dose and long-term for chronic pain, rates of dependence in the community could be high. Whether medicinal
cannabinoids have a role as substitution treatment in cannabis use disorder, analogous to opioid substitution treatment for opioid dependence, or for other substance use
disorders, is unclear at present.

Pregnancy
Placental transfer of cannabis to the fetus is known to occur,
although the exposure to cannabinoids is in smaller doses
compared to that of the mother. There are few data, however,
to indicate what effect cannabis speciﬁcally has on fetal development, because of substantial confounding by tobacco
and other signiﬁcant comorbid factors such as other substance use, mental health disorders, physical health conditions and psychosocial factors. Notwithstanding, deﬁnitive
evidence of premature birth, growth restriction or a neonatal
withdrawal syndrome in babies or signiﬁcant deﬁcits in early
childhood development has not been reported for those exposed in utero. With regard to breastfeeding, transfer of cannabinoids into breast milk does occur [8] and clinicians will
need to advise patients of the risks of exposing a child to a
lipid soluble drug known to affect brain development.

Driving
Cannabis has been associated with road trafﬁc accidents and
fatal injuries [9]. The effects of cannabis on motor coordination, reaction time, judgement and tracking ability are well
documented, but a deﬁnition of a threshold serum cannabinoid level that would be expected to impair most people’s
driving capacity remains elusive, complicated further by ﬁndings differing substantially between those recently exposed
to cannabis compared to cannabis-habituated individuals
[10]. It is therefore important for clinicians to inform patients
that driving is not recommended while taking medicinal
cannabinoids.
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Nonmedical cannabis use, and in particular THC, has been associated with depression, anxiety and psychosis [2]. This has
implications when cannabinoids are being considered for
therapeutic purposes. CBD, by contrast, has shown promising improvements in positive, negative and cognitive symptoms of schizophrenia with fewer extrapyramidal side
effects than antipsychotics currently available. CBD may
therefore serve as a useful alternative or adjunct medication
for psychosis and possibly a range of other mental health
conditions. Such hypotheses need to be tested with rigorous
clinical trials and robust evidence.

Administration of medicinal
cannabinoids
Data on cannabinoid components (e.g. THC:CBD ratio),
dosing and frequency regimen effective for various clinical
conditions are beginning to emerge. Cannabinoid effects
vary between products. Side-effects such as panic attacks,
short-term memory loss, tachycardia or hypertension may
occur even in recreational users but may be more severe in
those with complex conditions for which medicinal

Cannabis Use: risks including addiction

cannabinoids are prescribed, as the pharmacokinetics and
the pharmacodynamics are not well characterized in these
populations. Physicians also must decide on optimal mode
of administration; for example, smoking cannabis cannot
be recommended given the harmful products of combustion
[14]. The latter can be avoided through modes of administration such as vaporisation, oromucosal sprays or sublingual preparations (as in the case of nabiximols or Sativex).
These preparations also enable more immediate onset of
effect thus allowing titration of dose to optimal effect. Oral
formulations such as capsules and oils, less amenable to
titration, may also not be tolerated in the context of
profound nausea and vomiting characteristic of some conditions. The use of transdermal patches may have promise in
clinical contexts where slower onset but longer duration of
action is required. Physicians must also monitor potential
drug interactions as the evidence emerges; for example, in
the trial of CBD in children with Dravet Syndrome, hepatic
aminotransferase levels increased in patients on concomitant valproate [15].

Nonpharmaceutical grade medicinal
cannabinoids
In addition to the gradual emergence on the market of
approved pharmaceutical grade products containing cannabinoids in speciﬁed amounts, many people continue to consume illegal cannabinoid products of varying composition.
The latter can be harmful because of their unknown concentrations of cannabinoids, as well as inclusion of potentially
harmful contaminants and impurities [16]. In general, more
adverse effects might be expected from self-medication with
high potency cannabis products, particularly if used
frequently over the long-term.

In accordance with the principles of evidence-based
medicine, this will promote the effective and safe use of
cannabinoids.
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Conclusion
As greater understanding about the therapeutic potential of
cannabinoids emerges, their relevance to public health is
also increasing. Use of unknown concentrations of
cannabinoids for therapeutic purposes can potentially be
harmful. Urgent clinical issues that need to be addressed
include:
• High-quality scientiﬁc evidence regarding the therapeutic
effects of cannabinoids for speciﬁc conditions through rigorous clinical trials is essential to inform appropriate use
of cannabis-derived substances by physicians.
• Reliable and comprehensive monitoring of cannabinoids
that are being used for therapeutic purposes in different
countries with oversight of the appropriate regulation
agency (e.g. Food and Drug Administration, European
Medicines Evaluation Agency, Anvisa, Therapeutic Goods
Administration or equivalent) to ensure that the cannabinoids available to patients are of high quality and safe to use
• Prompt
communication
of
the
ﬁndings
of
pharmacovigilance activities to health professionals and
the community as they emerge to facilitate safe and effective translation for therapeutic purposes.
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